Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 402INDUSTRY 91NIH 65NETWORK 26UNKNOWN 4OTHER_GOV 3FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Prostatic Neoplasms 17Rare Diseases 3Neoplasms 3Neoplasm Metastasis 3Leukemia 3Recurrence 2Lymphoma 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Genetic Diseases, Inborn 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Squamous Cell 2Adenocarcinoma Of Esophagus 2Turcot syndrome 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Respiratory Aspiration 1Radiation Pneumonitis 1Prostate Cancer Diagnosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Oropharyngeal Neoplasms 1Oligodendroglioma 1Non-Muscle Invasive Bladder Neoplasms 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neuroma, Acoustic 1Neurologic Manifestations 1Neurofibromatosis 2 1Neurofibromatoses 1

Interventions

Streptozocin 1Mercaptopurine 1Carmustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × FED × Brain Neoplasms × Clear all
NCT00004688 2015-03-25

Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms

FDA Office of Orphan Products Development

Phase 2 Completed
35 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Genetic Diseases, Inborn, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡